Home » Stocks » CYTR

CytRx Corporation (CYTR)

Stock Price: $2.40 USD -0.02 (-0.83%)
Updated Jan 15, 2021 3:59 PM EST - Market closed
Market Cap 87.55M
Revenue (ttm) n/a
Net Income (ttm) -8.28M
Shares Out 35.20M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.40
Previous Close $2.42
Change ($) -0.02
Change (%) -0.83%
Day's Open 2.57
Day's Range 2.31 - 2.60
Day's Volume 355,176
52-Week Range 0.35 - 2.75

News

Hide News
  • All
  • Videos
  • Press Releases
Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...

Other stocks mentioned: ORPH
Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurod...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today h...

About CYTR

CytRx Corporation, a biopharmaceutical company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstre... [Read more...]

Industry
Biotechnology
IPO Date
Nov 10, 1986
CEO
Steven Kriegsman
Employees
4
Stock Exchange
OTCMKTS
Ticker Symbol
CYTR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CYTR is 4.50, which is an increase of 87.50% from the latest price.

Price Target
$4.50
(87.50% upside)